Valuation models
price $253.62 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused284.12 – 527.68370.4232% undervaluedDCF · Perpetuity growth · 10y292.55 – 532.61377.7633% undervaluedDCF · EBITDA exit · 5y327.39 – 358.38342.4626% undervaluedDCF · EBITDA exit · 10y326.94 – 384.82354.4828% undervaluedP/E · peers192.58 – 528.18244.984% overvaluedP/E · own history136.50 – 253.86209.4921% overvaluedPEG—233.848% overvaluedEV/EBITDA · peers307.83 – 630.21365.2131% undervaluedEV/Revenue · peers269.25 – 952.13412.2338% undervaluedEarnings power value216.73 – 361.52272.257% undervaluedWall St. consensus target—258.502% belowCost of capital (WACC)—6.43%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
370.42
Biogen closed at $253.62 — undervalued by 32% vs model.
284.12the model's range527.68
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
209.49 – 412.23
Wall St. target
258.50 2% below
Below model, 1y
30 of 30 days
How it is valued
Valued asMature & stable
Revenue declining (~-0% recent)Moderate margins (13% net margin)Highly cyclical earningsStrong FCF yield (5.5%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.